REDWOOD CITY, Calif., Aug. 7 /PRNewswire-FirstCall/ -- FoxHollow Technologies , which manufactures and markets the SilverHawk(TM) Plaque Excision System, a minimally invasive device for the treatment of peripheral artery disease (PAD), is scheduled to participate in the 26th Annual Canaccord Adams Summer Seminar on Wednesday, August 9, 2006, in Boston, Massachusetts.
Dr. John Simpson, chief executive officer, along with Matt Ferguson, chief financial officer, will provide an update on the company at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
A live audio webcast of the presentation will be available via the Internet at http://investor.foxhollowtech.com and will be available for replay for approximately three months.
About FoxHollow Technologies
FoxHollow Technologies, Inc., develops and markets minimally invasive plaque excision devices for the treatment of peripheral artery disease (PAD). An estimated 12 million people in the U.S. are thought to suffer from PAD, with 2.5 million patients currently diagnosed. PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The company’s SilverHawk system is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet. For more information, please visit our website at http://www.foxhollowtech.com
Contacts Investor Relations: Matt Ferguson Chief Financial Officer 650-421-8449 investorrelations@foxhollowtech.com Media Relations: Robin Gaffney 650-421-8614 rgaffney@foxhollowtech.com
FoxHollow Technologies, Inc.
CONTACT: investors, Matt Ferguson, Chief Financial Officer,+1-650-421-8449, or investorrelations@foxhollowtech.com, or media, RobinGaffney, +1-650-421-8614, or rgaffney@foxhollowtech.com, both of FoxHollowTechnologies, Inc.
Web site: http://www.foxhollowtech.com/
